The aim of our study was to assess the clinical efficacy and toxicity of ibandronate in the management of symptomatic skeletal metastases due to prostate cancer (PCA). Twenty-five patients with painful osseous metastases due to hormone refractory PCA (HRPCA) were treated with 6 mg ibandronate every 4 weeks in an open prospective non-randomized clinical study. Primary study endpoint was pain reduction documented by the use of a 10-point visual analog scale. Palliative response with significant reduction in pain score from 6.5 (5 -10) to 2.0 [(0 -4), P < 0.001] was achieved in 23 (92%) patients; nine patients (39%) were completely pain free. Bisphosphonate treatment of painful osseous metastases due to HRPCA resulted in a significant pain reduction and a significant decrease of daily consumption of analgesics in 92% of the patients. Both characteristics are paralleled by an increase in Karnofsky index mainly due to better mobility. Bisphosphonates should have a definite role in the palliative management of symptomatic HRPCA.
Introduction
Prostate cancer (PCA) is the most prevalent tumor in men and despite increasing efforts at early detection 10 -20% of the cases will already harbor metastases at time of diagnosis. 1 In most patients, hormone refractory PCA (HRPCA) will develop 18 -36 months after initiation of androgen deprivation therapy. 2 The clinical picture of HRPCA is dominated by osseous metastasis in 90 -95% of cases resulting in bone pain, pathological fractures, spinal cord compression, weight loss, anemia and thrombocytopenia. 3 As there are no curative treatment options effective reduction of bone pain appears to be of utmost importance to improve quality of life and performance status in order to enable a normal lifestyle.
Although, there are a variety of treatment options available, side effects of the chosen therapeutic approach should be minimal, therapeutic efficacy should be optimal considering a median survival of only 32 weeks in the presence of painful osseous metastases. On the basis of experimental and clinical studies it has been documented that PCA in bone is an osteolytic as well as osteoblastic disease 4 resulting in osteosclerosis and increased bone volume in the presence of wholesale destruction of normal bone.
Bisphosphonates (BP) are potent inhibitors of normal and pathological bone resorption 5 and they directly exert an inhibitory effect on mature osteoclasts; recent studies suggest that osteoblasts exposed at the bone surface could also be essential target cells for BPs with secondary effects on osteoclasts. 4, 5 Recently, we have demonstrated that clodronate exerts an effective pain relieving effect in 75% of patients with HRPCA and painful bone metastases. 6 Since ibandronate is approximately 50 times more potent than pamidronate and 500 times more potent than clodronate in inhibiting osteoclastic bone resorption in animal models, 7,8 the present study was designed to assess the analgesic efficacy and toxicity of high dose ibandronate in HRPCA with painful osseous metastases.
Patients and methods
Twenty-five patients with symptomatic skeletal metastases from HRPCA were treated with i.v. ibandronate in an open, prospective, non-randomized study. The mean age of the patients was 69 (45 -75) y; 13 patients had received hormonal therapy by surgical castration, 12 patients were initially on LHRH analogues. All patients suffered from HRPCA as documented by a prostate specific antigen (PSA) progression on three consecutive measures. Mean PSA serum concentration was 524.2 ng/ dl (6.0 -3610). All patients had a life expectancy of at least 3 months and were capable of completing pain scales and the diary of analgesic consumption.
Additional therapeutic measures after initial PSA rise had been estramustine phosphate [960 mg/d, n ¼ 15], mitomycin [20 mg/m 2 , n ¼ 7], and liposomal pegylated doxorubicin [40 mg/m 2 , n ¼ 3]; however, therapy had been stopped due to PSA progression in all patients at least 4 weeks before entering the study protocol.
Patients had an initial adjustment and stabilization of their analgesic medication. They were assessed by a physical examination, completion of pain scores and standard blood tests (see inclusion criteria).
Patients were excluded from the study if they had evidence of significant renal impairment (serum creatinine > 2.5 mg/dl) and if they were treated with bisphosphonates during the preceeding 3 months or cytotoxic drugs during the preceeding 4 weeks.
Inclusion criteria
When entering the study protocol all patients underwent meticulous laboratory work-up to ensure adequate renal, hepatic and hematological function; PSA serum levels were analyzed. Serum levels of calcium, albumin, creatinine, phosphate, alkaline phosphatase, transaminases and electrolytes were determined prior to therapy and at days 1, 7 and 28. Full blood count was measured before treatment and again at days 7 and 28 and repeated every 4 weeks. All biochemical and hematological investigations were performed using standard automated techniques.
All patients underwent bone scintigraphy to document the extent of osseous involvement; all bones exhibiting hot spots were evaluated radiologically in order not to miss metastases being at high risk for pathological fracture.
Severity of bone pain was assessed by the patients using a visual analogue scale (VAS) extending from 0 (no pain) to 10 (severe pain); the general condition was evaluated by Karnofsky-index and ECOG (Eastern Cooperative Oncology Group) performance status. All patients were continuously assessed for adverse effects. The daily use of analgesics -if there was any -was recorded in a diary, and the patients were instructed how to use the diary.
Treatment
All patients continued their primary androgen ablation therapy (orchiectomy, luteinizing hormone releasing agonists, estrogens or cyproteronacetat); however, antiandrogens such as flutamid or biclutamid were stopped 4 weeks and 6 weeks prior to BP therapy.
Patients continued their analgesic medication and adjusted the dosage over a 14-day period to achieve optimal pain control.
Ibandronate treatment was started with an i.v. saturation phase for 3 days; patients received 6 mg ibandronate in 500 ml 0.9% saline solution for 1 h each day for 3 days. Treatment was continued with 6 mg ibandronate every 4 weeks.
Evaluation of efficacy
To evaluate the analgesic effect of ibandronate, patients had to assess the severity of bone pain using a VAS from 0 to 10. The primary criterion of response was pain relief for at least two consecutive visits.
Patients received a diary to record the daily analgesic requirements; if the patients initially were using analgesics, medication was retained and the dose was adjusted following response or non-response to BP therapy.
Other end points of the study were duration of response as defined by the time interval from the first measurable pain reduction on VAS until the first documented increase in bone pain.
Each additional analgesic measure such as radiation was recorded and evaluated.
Follow-up
Patients were seen at 4-week intervals to document PSA serum levels, liver enzymes, creatinine, urea nitrogen, alkaline phosphatase, calcium and phosphate. Karnofsky index and ECOG performance status were analyzed, bone pain was assessed using the VAS and side effects as well as subjective tolerability was recorded.
Quality-of-life was documented using the EORTC QLQ-30 questionnaire which was recorded at 4-week intervals.
In the case of pain recurrence radiological studies were undertaken to exclude metastases being at risk for pathological fractures; in the case of pathological fractures, surgical correction or palliative local radiation was performed. In cases without detected fractures, pain management was altered and patients received a combination of mitoxantrone (12 mg/m 2 ) and prednisolone (20 mg/day). For statistical analysis (parametric and non parametric) of changes of the pain scale the paired t-test was used comparing the mean data from all patients before therapy and at different intervals during treatment.
Results
Significant bone pain was initially present in all patients with a mean pain score of 6.5 (5 -10). Significant pain reduction to a mean pain score of 2.0 (0 -4) was achieved in 23 patients (92%, P < 0.001). Nine patients (39.1%) were completely pain free without further need for analgesic medication, and 14 patients (60.9%) experienced a significant decrease of their daily consumption of analgesic drugs. On average, the first analgesic effect of ibandronate was observed at day 3 (1 -5) of parenteral therapy. Only two patients not responding to ibandronate needed additional analgesic measures with the regular use of fentanyl patches.
The improvement on bone pain was paralleled by an increase in Karnofsky index (KI) and ECOG performance status. The initial mean KI of 55% (30 -60%) increased to a mean KI of 80% (50 -80%); increase of KI was primarily due to increased mobility of the patients.
ECOG performance status improved from 2.9 (2 -4) to 1.3 (0 -2) primarily due to improved mobility.
There were two non-responders (8%)
Currently, none of the treated patients have died; however, there was no impact of ibandronate treatment on the reduction of PSA serum levels. The mean duration of analgesic action was 24 weeks (16 -43) .
Besides an asymptomatic decrease of serum calcium levels in three patients (12%) during the initial i.v. saturation phase no significant changes could be observed for liver enzymes, urea nitrogen, creatinine and hematological parameters.
Side effects consisted mainly of fever on the day following i.v. application of ibandronate in four patients (16%). In none of the cases did the therapy need to be discontinued due to adverse side effects. There were no injection site reactions and none of the patients experienced other systemic side effects.
Discussion
Morbidity and death from PCA is commonly related to its predeliction to form skeletal metastases as indicated by the fact that up to 84% of patients dying from PCA harbor osseous metastases. 3 PCA cells stimulate osteoblasts as well as osteoclasts due to specific mitogenic factors in a paracrine fashion. Overactivity of osteoblasts results in a marked increase of bone volume and the classic sclerotic appearance of metastases on radiographs in most cases. 4 Increased osteoclast activity due to paracrine stimuli by growth factors (EGF, TGFa, PDGF) secreted by osteoblasts 9,10 is responsible for major bone destruction. These data are substantiated by histomorphometric studies of bone metastases from HRPCA obtained by iliac crest biopsies demonstrating a typical osteoclast effect in metastatic deposits as demonstrated by Clarke et al; 4 control biopsy specimens obtained following pamidronate treatment exhibited a typical bisphosphonate effect with rounded multinucleated cells disengaged from the bone surface, a significant decrease in bone breakdown and the preservation of tumor-free bone volume.
The application of bisphosphonates appears to be an effective palliative measure for pain relief in patients with painful skeletal metastases due to various types of cancer. 11, 12 Earlier studies by Purohit et al 11 6 We achieved a significant pain reduction and a significant decrease of daily consumption of analgesics in 75% of patients treated with clodronate. In the previous study, improvement of bone pain was paralled by an improvement in KI from 45 to 70% at the end of the treatment period mainly due to decreased skeletal pain. The application of clodronate, however, was hampered by gastrointestinal side effects in 18% of the patients necessitating discontinuation in 6%. Ibandronate is a new generation bisphosphonate that is approximately 50 times more potent than pamidronate and 500 times more potent than clodronate. 7, 8 We found the i.v. application of 6 mg ibandronate to be a highly effective and well tolerated treatment of painful osseous metastases due to HRPCA with a positive response in 92% of the patients. Comparing the results of our previous clodronate study with the current data, response rates are significantly higher and side effects occur less frequently so that ibandronate should be preferentially used for pain management.
All together, the overall response of ibandronate compares favorably with that of other bisphosphonates used to treat painful osseous metastases in HRPCA 13 -19 (Table  1) . The large variation of response rates most probably reflects the analgesic potency of the applied bisphosphonate and patient selection. As has been demonstrated by our previous study, the application of bisphosphonates only results in significant pain reduction if extraosseous metastases with infiltration of soft tissue or nerve compression have been excluded prior to therapy. 6 Furthermore, patients with extensive bone metastases (ECOD score 4) and patients with a poor general conditions showed a negative response to clodronate. 6 The rationale to use a dose of 6 mg ibandronate derives from the dose -response studies in the treatment of cancer-associated hypercalcemia. 20 -23 These investigations reported on a significantly reduced efficacy to restore normocalcemia in tumors other than breast cancer and hematological tumors since the osteolytic process responsible for hyperclacemia appears to be predominantly humeral in solid tumors; 21 hematological malignancies show mainly local osteolytic mechanisms and breast cancer demonstrates a mixed osteolytic process involved in hypercalcemia. 22, 23 These hypothetical findings are paralleled by measurable disturbances in calcium metabolism in patients with PCA. 24 -27 Due to the osteoblastic overactivity, there is an increased calcium uptake by the skeleton which has to be compensated by homeostatic mechanisms of increased intestinal calcium uptake and increased osteoclast activity in tumor free bone areas in order to maintain physiological calcium serum levels. Recently, our group showed that osteoblastic overactivity is paralleled by a significantly increased serum concentration of osteocalcin and alkaline phosphatase as compared to healthy volunteers. 27 Furthermore, increased bone turnover was reflected by significantly elevated urinary excretions of hydroxyproline and pyridinium crosslinks in PCA patients.
Treatment associated toxicity was mild with low grade fever following the day after i.v. application being the most common side effect in approximately 20% of the patients. We did not observe any significant adverse reactions with regard to liver and renal function or with regard to hematological studies.
The clinical application of BP in the palliative management of painful bone metastases due to HRPCA has to be balanced against other palliative therapeutic options available. Currently, the combination of mitoxantrone and corticosteroids appears to be standard care for these patients in the US. 28, 29 With regard to mitoxantrone/corticosteroids, two large prospectively randomized clinical trials comprising 402 patients have been published recently demonstrating a good palliative response. 28, 29 However, although the patients enrolled in the trial published by Tannock et al 28 had a better performance status than our patient cohort, the criterion of palliative response was met in only 29% of the patients with a mean duration of response of 43 weeks; another 9% of the patients experienced a decrease of at least 50% in analgesic score with a mean duration of 33 weeks making up for a total response rate of 38%. As demonstrated in our study the overall response rate in terms of pain reduction was 75% with 19 (22.3%) patients being completely pain free. Therefore, BP treatment of painful osseous metastases appears to be equal to mitoxantrone/prednisolone therapy. The short duration of pain response in our patients most probably was due to the poor general condition of the patients, the massive extent of osseous metastases and the presence of non-skeletal painful metastases.
Besides therapeutic efficacy, therapy associated side effects have to be considered in a palliative setting. Whereas the side effects of BP treatment primarily consist of gastrointenstinal problems in 18% of the patients, a high number of patients will experience hematological side effects with mitoxantrone. Tannock et al 28 reported 46% of the patients experiencing granulocytopenia or neutropenic sepsis in the course of therapy. Kanthoff et al 29 documented WHO grade 3/4 hematotoxicity in even 59% of the patients. Another 15% of the patients might develop cardiac abnormalities if the cumulative dose of mitoxantrone exceeds 100 mg/m 2 or approximately nine cycles. Gastrointestinal side effects such as nausea and vomiting were reported in 29% of the patients during the whole treatment period.
Based on our results, ibandronate represents an effective drug in the palliative management of patients with painful skeletal metastases due to HRPCA.
Conclusion
Bone metastases in advanced HRPCA are a major clinical problem with significant morbidity and reduction of quality of life. The effect of metastases on the skeleton can be modulated by the use of bisphosphonates resulting in a significant reduction of pain, improvement of general health status and mobility and a diminuition of osteolysis. The 90% response rate of third generation bisphosphonates such as ibandronate appears to be even higher than the clinical results of chemotherapeutic protocols with palliative intent. In order to prove the clinical utility of bisphosphonates, we have initiated a clinical phase III study randomizing 180 patients with HRPCA and painful osseous metastases to receive either ibandronate at 6 mg in 4-week intervals or mitoxantrone/prednisolone at 12 mg/m 2 in 3-week intervals. The future perspective of BP in the management of HRPCA might be in the very early application at time of asymptomatic PSA rise following androgen deprivation or even in the adjuvant setting in high-risk patients with locally advanced prostate cancer following radical prostatectomy since a number of animal studies have demonstrated a preventive effect of bisphosphonates in the formation of bone lesions. 30 
